Sirolimus and CsA facilitate donor engraftment in anti-CD40L–treated mice conditioned with 100 cGy TBI
| Reagent . | No. chimeric . | % donor . | Range . |
|---|---|---|---|
| Experiment 1 | |||
| Hamster IgG | 0/20 | 0 ± 0 | NA |
| Anti-CD40L | 9/19* | 16 ± 18* | 9 -46 |
| Sirolimus | 0/10† | 0 ± 0† | NA |
| Anti-CD40L + sirolimus | 20/20*,† | 48 ± 5*,† | 37 -59 |
| Sirolimus + anti-CD4 | 9/10*,† | 38 ± 14*,† | 35 -53 |
| Sirolimus + anti-CD8 | 0/10† | 0 ± 0† | NA |
| Experiment 2 | |||
| Hamster IgG | 0/20 | 0 ± 0 | NA |
| Anti-CD40L | 12/19* | 24 ± 20* | 30 -45 |
| CsA | 1/19† | 1 ± 3† | 15 |
| Anti-CD40L + CsA | 18/19*,† | 31 ± 11* | 10 -40 |
| CsA + anti-CD4 | 10/10*,† | 30 ± 11* | 3 -43 |
| CsA + anti-CD8 | 0/10† | 0 ± 0† | NA |
| Reagent . | No. chimeric . | % donor . | Range . |
|---|---|---|---|
| Experiment 1 | |||
| Hamster IgG | 0/20 | 0 ± 0 | NA |
| Anti-CD40L | 9/19* | 16 ± 18* | 9 -46 |
| Sirolimus | 0/10† | 0 ± 0† | NA |
| Anti-CD40L + sirolimus | 20/20*,† | 48 ± 5*,† | 37 -59 |
| Sirolimus + anti-CD4 | 9/10*,† | 38 ± 14*,† | 35 -53 |
| Sirolimus + anti-CD8 | 0/10† | 0 ± 0† | NA |
| Experiment 2 | |||
| Hamster IgG | 0/20 | 0 ± 0 | NA |
| Anti-CD40L | 12/19* | 24 ± 20* | 30 -45 |
| CsA | 1/19† | 1 ± 3† | 15 |
| Anti-CD40L + CsA | 18/19*,† | 31 ± 11* | 10 -40 |
| CsA + anti-CD4 | 10/10*,† | 30 ± 11* | 3 -43 |
| CsA + anti-CD8 | 0/10† | 0 ± 0† | NA |
B6 mice were irradiated with 100 cGy TBI on day − 1 and infused with 40 × 106 BALB/c BM on day 0. Reagents were administered from day − 1 through day 14. PBLs were typed for percentage of donor-host at 3.5 months after BMT. Chimeric is defined as more than 3% donor PBLs. Percentage donor is defined as average percentage of donor cells of all mice in the group ± 1 SD. Range indicates lowest to highest level of percentage donor cells in engrafted mice. NA indicates not applicable.
P < .001 compared with hamster IgG.
P ≤ .044 compared with anti-CD40L as a single agent.